ESMO Congress 2026

October 23–27, 2026 · Madrid · 176 items

Madrid floor. One post is one item; several people on the same trial or drug become a heat probe. The floor is paged by day; prelude discussion sits on the prelude board. Abstracts are linked, not reprinted, and other people's slides are not posted.

TodayOct 23Fri

Friday · 30 items

09:42
National Cancer Centre Singapore@NCCS_SGScore6060
Proud of our #NCCS team for representing Singapore on the global stage at #ESMO2026 in Madrid!🎉 Our researchers and clinicians are bringing their best to this year's @myESMO Annu…
#NCCSHeat 00 likes0 replies0 reposts
09:11
Singapore Society of Oncology@SSO_SingaporeScore6060
#ESMO2026 #Oncology #CancerAwareness #CancerTreatments #SSO #SSOSingapore #SingaporeSocietyOfOncology
#CANCERAWARENESS #CANCERTREATMENTS #SSOSINGAPORE #SINGAPORESOCIETYOFONCOLOGYHeat 00 likes0 replies0 reposts
07:56
Dr Amol Akhade@SuyogCancerScore6060
🚨 ESMO 2026 | PANKU-Breast01 (LBA50) #esmo26 Impressive phase III results for izalontamab brengitecan (iza-bren), a bispecific EGFR/HER3 ADC, in previously treated MBC HR +ve Her2…
Same topic PANKU-BREAST01 · 2 people LBA50 izalontamab brengitecan EGFR HER2Heat 22 likes0 replies0 reposts
07:24
Jeff Ryckman@jryckman3Score6060
RADIANT trained on 119,782 RT cases and tested segmentation, dose and outcome prediction across sites. What I want next is clinical utility: does using it improve planning decisio…
Heat 00 likes0 replies0 reposts
07:21
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@bradloncar Target was 0.6. Delivered 0.58 (95% CI 0.45–0.75), with DMFS 0.62. Beat the bogey, stock down 17%. Pretty clean natural experiment in "sell the news" vs. actual data. #…
Heat 00 likes0 replies0 reposts
07:19
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@EricTopol @statnews @adamfeuerstein Small correction: 82% vs 70% is 2-year recurrence-free survival (vaccine arm higher), not mortality. No OS data yet. And the population is rese…
Heat 00 likes0 replies0 reposts
07:19
Katy Beckermann@katy_beckermannScore6060
✈️ En route to Madrid for #ESMO26, landing just in time for the data to start Friday morning. Most excited for: VOLGA LBA2 in bladder cancer, INTerpath-001's first phase 3 neoantig…
Same topic VOLGA · 6 people INTERPATH-001 LITESPARK-011 DASL-HICAP LBA2 #GUONCHeat 1411 likes0 replies3 reposts
07:16
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@michaelzlin Look at the numbers at risk: at 30 mo it's 10 vs 3 patients, at 35 mo it's 0 vs 0. That "convergence" is one or two events in a handful of people — the CI there is the…
Heat 00 likes0 replies0 reposts
07:13
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@Biohazard3737 The 42% is relative. In absolute terms: 2-yr RFS 82% vs 70%, i.e. ~1 in 8 patients spared a recurrence. For adjuvant melanoma that's a big number — "cure" was never …
Heat 00 likes0 replies0 reposts
07:07
Jeff Ryckman@jryckman3Score6060
FURTHER enrolled 69/129 planned pts. At 2wk, pain response 50% in pooled MR-HIFU arms vs 38% with EBRT (P=.41). Just refer these folks for EBRT. Most data for invasive ablation …
Heat 22 likes0 replies0 reposts
07:07
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@A_May_MD @deathtouch2k Agreed — but the H2H isn't vaccine vs neoadjuvant, it's neoadjuvant ± vaccine. The product is built from the resected tumor, so it sits on top of whatever c…
Heat 00 likes0 replies0 reposts
07:07
Medable@medableincScore6060
Let’s go #ESMO26!
Heat 00 likes0 replies0 reposts
07:05
Jeff Ryckman@jryckman3Score6060
GORTEC IDEAL is early: induction EGFR-ADC +/- anti-PD1, then 70 Gy/cisplatin. G3 TEAEs in 6/10 combination pts vs 2/10 ADC alone. 20 pts in this safety analysis. #ESMO26 #radonc
EGFRHeat 00 likes0 replies0 reposts
07:04
Jeff Ryckman@jryckman3Score6060
KEYNOTE-412 ctDNA: clearance after 5wk CRT was more frequent w/ pembro, but outcome associations varied by HPV status and arm. Interesting biomarker work. Without an interaction t…
KEYNOTE-412Heat 00 likes0 replies0 reposts
07:04
Jeff Ryckman@jryckman3Score6060
GY020 didn't meet its primary endpoint: 3y success 70% w/ pembro+RT vs 73% RT alone. Leaving study counted as failure. KM RFS numerically favored pembro, but CI crossed 1. G3/4 to…
GY020Heat 00 likes0 replies0 reposts
07:03
Jeff Ryckman@jryckman3Score6060
UNION: 3y EFS 91% vs 77% with SCRT/CAPOX/camrelizumab vs long-course CRT/CAPOX in rectal cancer. HR 0.33 (95% CI 0.15-0.71). Impressive signal. But RT schedule and IO both changed…
Same topic UNION · 3 people camrelizumabHeat 00 likes0 replies0 reposts
07:03
Jeff Ryckman@jryckman3Score6060
Encouraging pancreas SBRT data from MASTERPLAN. Adding 40 Gy/5 fx cut 12mo locoregional recurrence from 52% to 20% (P=.022). OS 22 vs 14mo, but this is a 74-pt phase II with mixed…
Same topic MASTERPLAN · 2 people 12MO 14MOHeat 00 likes0 replies0 reposts
07:03
Jeff Ryckman@jryckman3Score6060
ARION adds to the negative IO+CRT story in esophageal cancer. Durvalumab + FOLFOX/50 Gy in 25 fx: PFS HR 0.91 (95% CI 0.55-1.49), OS HR 0.99. Only 112 pts, mostly SCC. No demons…
Same topic ARION · 2 people durvalumabHeat 00 likes0 replies0 reposts
07:02
Jeff Ryckman@jryckman3Score6060
KEYNOTE-975: adding pembro to definitive CRT didn't improve EFS in CPS>=10 esophageal/GEJ cancer. HR 0.97 (95% CI 0.77-1.23). Hierarchy stopped there; OS wasn't formally tested. A…
Same topic KEYNOTE-975 · 3 peopleHeat 00 likes0 replies0 reposts
07:02
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@A_May_MD @deathtouch2k Same HR, different trials. S1801: phase 2, n=313, clinically detectable III–IV, EFS. INTerpath-001: phase 3, n=1137, resected IIB–IV incl. node-negative IIB…
Same topic INTERPATH-001 · 11 peopleHeat 00 likes0 replies0 reposts
07:02
Jeff Ryckman@jryckman3Score6060
Median OS 36.2mo in INSPIRE-LM is striking: 30 pts w/ HER2+ breast LM treated w/ IT trastuzumab + pertuzumab. 29/30 also had WBRT or proton CSI. Single-arm study. Encouraging, but…
2MO trastuzumab pertuzumab HER2Heat 00 likes0 replies0 reposts
07:01
Jeff Ryckman@jryckman3Score6060
In resected brain mets progressing after RT: fewer CD8+ cells and more FOXP3+ cells than untreated tumors. These are selected treatment failures. I wouldn't read this as evidence …
Heat 00 likes0 replies0 reposts
07:01
Jeff Ryckman@jryckman3Score6060
Trotabresib added toxicity without helping newly diagnosed GBM. 12mo PFS 22% vs 39% w/ RT+TMZ alone (P=.048); OS similar. G3+ thrombocytopenia 37% vs 15%. #ESMO26 #radonc
12MOHeat 11 like0 replies0 reposts
06:59
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@RNAiAnalyst @A_May_MD Biologically plausible: ~6 wks to manufacture + time to mount a T-cell response, so early relapses happen before the vaccine can act. But a 6-month landmark …
Heat 00 likes0 replies0 reposts
06:59
Jeff Ryckman@jryckman3Score6060
14.8% invasive local recurrence at 5y after BCS alone in TOP-1. Age 70+, small low-grade ER+ tumors, no RT or ET. Most recurrences were salvaged, but that is still more treatmen…
Heat 00 likes0 replies0 reposts
06:56
Yakov Pakhomov MD, PhD@yakov_pakhomovScore6060
@adamfeuerstein Fair point on the control arm: for macroscopic stage III, neoadjuvant IO is now the bar (NADINA/S1801). But resected IIB/C and microscopic stage III have no neoadju…
NADINA INTERPATH-001Heat 00 likes0 replies0 reposts
06:42
Jeff Ryckman@jryckman3Score6060
🚨SANO 5y: surveillance vs surgery after cCR OS 50% vs 54% (NS) Distant mets 46% vs 29% (P<.01) Reminder: only 41.4 Gy/23 fx, a pre-op, arguably non-definitive dose, especially w…
SANOHeat 107 likes0 replies3 reposts
06:02
Krishan Jethwa@KrishanJethwaScore6060
🚨UNION Trial🚨 Locally advanced rectal cancer N=231 🔍Randomized 🔵Chemoradiation➡️2c CAPOX➡️TME➡️6c CAPOX 🟢SCRT➡️2c CAPOX + camrelizumab ➡️TME➡️6c CAPOX+ cam 🔥SCRT + chemo-IO demo…
Same topic UNION · 3 people camrelizumabHeat 85 likes0 replies3 reposts
05:59
AJMC@AJMC_JournalScore6060
Adding Merck/Moderna’s individualized mRNA therapy intismeran to pembrolizumab cut the risk of recurrence or death by 42% in resected stage IIB-IV melanoma, per full phase 3 INTerp…
Same topic INTERPATH-001 · 11 people pembrolizumabHeat 00 likes0 replies0 reposts
05:55
Krishan Jethwa@KrishanJethwaScore6060
🔥AGITG MASTERPLAN🔥 Borderline resectable or Locally advanced PDAC n=75 🔍Randomized 3m mFOLFIRINOX or Gem+nab-Paclitaxel alone +/- SBRT (40 Gy/5 fx) Primary endpoint: locoregiona…
Same topic MASTERPLAN · 2 people paclitaxelHeat 00 likes0 replies0 reposts